

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 November 2023 (23.11.2023)



(10) International Publication Number
WO 2023/223097 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2023/000277

(22) International Filing Date:
19 May 2023 (19.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/344,455 20 May 2022 (20.05.2022) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **BURGER, Matthew, T.**; Novartis Institute For Biomedical Research, Inc., 250, Massachusetts Avenue, Cambridge, MA 02139 (US). **CHEN, Zhuoliang**; Novartis Institute For Biomedical Research, Inc., 250, Massachusetts Avenue, Cambridge, MA 02139 (US). **D'ALESSIO, Joseph, Anthony**; Novartis Institute For Biomedical Research, Inc., 250, Massachusetts Avenue, Cambridge, MA 02139 (US). **HOLLINGWORTH, Gregory, John**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **KLINTER, Claudia, Judith**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **LANGLOIS, Jean-Baptiste**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **MCNEILL, Eric**; Novartis Institute For Biomedical Research, Inc., 250, Massachusetts Avenue, Cambridge, MA 02139 (US). **MUNDT, Cornelia, Anne**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **NAKAJIMA, Katsumasa**; Novartis Institute For Biomedical Research, Inc., 250, Massachusetts Avenue, Cambridge, MA 02139 (US). **MADÖRIN, Katharina**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **YU, Bing**; 20 Eliot Road, Belmont, MA 02478 (US). **ZHANG, Qiang**; Novartis Institute For Biomedical Research, Inc., 250, Massachusetts Avenue, Cambridge, MA 02139 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ANTIBODY DRUG CONJUGATES

(57) Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) comprising an antibody or an antigen-binding fragment thereof covalently linked to two pharmaceutically active drugs through a dual linker. Linker-drug conjugates comprising the dual linker and the pharmaceutically active drugs are also disclosed. Such linkers are a convenient way of delivering two (e.g. two different or two of the same) drugs connected to a single antibody. Such linkers may be particularly useful in improving the solubility of antibody drug conjugates (ADCs) which comprise one or more hydrophobic drug compounds.

WO 2023/223097 A1